美国食品药品监督管理局（FDA）拒绝批准Corcept医疗针对罕见激素紊乱症研发的新药，这一重磅消息直接引发该公司股价在盘前交易时段断崖式下跌34.5%。市场对此反应剧烈，投资者纷纷抛售持股，反映出对该公司短期前景的深度担忧。
美国食品药品监督管理局（FDA）拒绝批准Corcept医疗针对罕见激素紊乱症研发的新药，这一重磅消息直接引发该公司股价在盘前交易时段断崖式下跌34.5%。市场对此反应剧烈，投资者纷纷抛售持股，反映出对该公司短期前景的深度担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.